Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 19/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 10/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1338579 | 0.84 | CA9 (0.45) | S1PR1 | |
| SCHEMBL1336495 | 0.79 | S1PR1 (0.43) | S1PR1S1PR3ALDH1A1TP53 | |
| SCHEMBL1338632 | 0.78 | S1PR1 (0.40) | S1PR1S1PR3SMN1; SMN2LMNA | |
| SCHEMBL1337404 | 0.78 | S1PR1 (0.37) | S1PR1S1PR3ALDH1A1MAPT | |
| SCHEMBL1338060 | 0.77 | S1PR1 (0.42) | S1PR1S1PR3 | |
| SCHEMBL1856300 | 0.77 | S1PR1 (0.58) | S1PR1S1PR3NPC1ALDH1A1MAPT | |
| SCHEMBL1337442 | 0.77 | S1PR1 (0.52) | S1PR1S1PR3 | |
| SCHEMBL1338343 | 0.77 | S1PR1 (0.46) | S1PR1S1PR3 | |
| SCHEMBL1338348 | 0.76 | ALOX5AP (0.43) | S1PR1S1PR3NPC1MAPTSMN1; SMN2 | |
| SCHEMBL13263744 | 0.75 | S1PR1 (0.45) | S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2387571-A1 | OXADIAZOLE DERIVATIVES AS SLPL RECEPTOR AGONISTS | Almirall S.A. (ES) | 2011-11-23 | — | — | EP | claimed |
| US-20110274657-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR ANTAGONISTS | ALMIRALL, S.A. (ES) | 2011-11-10 | — | — | US | claimed |
| US-8041930-B2 | Data processing apparatus and method for controlling thread access of register sets when selectively operating in secure and non-secure domains | ARM LIMITED (GB) | 2011-10-18 | — | — | US | claimed |
| EP-2210890-A1 | Oxadiazole derivatives as S1P1 receptor agonists | Almirall, S.A. (ES) | 2010-07-28 | — | — | EP | claimed |
| WO-2010081692-A1 | OXADIAZOLE DERIVATIVES AS SLPL RECEPTOR AGONISTS | ALMIRALL, S.A. (ES) | 2010-07-22 | — | — | WO | claimed |
| EP-2387571-A1 | OXADIAZOLE DERIVATIVES AS SLPL RECEPTOR AGONISTS | Almirall S.A. (ES) | 2011-11-23 | — | — | EP | disclosed |
| US-20110274657-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR ANTAGONISTS | ALMIRALL, S.A. (ES) | 2011-11-10 | — | — | US | disclosed |
| US-20110274657-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR ANTAGONISTS | ALMIRALL, S.A. (ES) | 2011-11-10 | — | — | US | disclosed |
| US-20110274657-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR ANTAGONISTS | ALMIRALL, S.A. (ES) | 2011-11-10 | — | — | US | disclosed |
| US-8041930-B2 | Data processing apparatus and method for controlling thread access of register sets when selectively operating in secure and non-secure domains | ARM LIMITED (GB) | 2011-10-18 | — | — | US | disclosed |
| EP-2210890-A1 | Oxadiazole derivatives as S1P1 receptor agonists | Almirall, S.A. (ES) | 2010-07-28 | — | — | EP | disclosed |
| WO-2010081692-A1 | OXADIAZOLE DERIVATIVES AS SLPL RECEPTOR AGONISTS | ALMIRALL, S.A. (ES) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110274657-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR ANTAGONISTS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR3 2/4885NPC1 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.